Truist Financial Maintains Sangamo Therapeutics(SGMO.US) With Hold Rating
TD Cowen Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating
A Quick Look at Today's Ratings for Sangamo Therapeutics(SGMO.US), With a Forecast Between $1 to $5
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $5
RBC Capital Remains a Hold on Sangamo Biosciences (SGMO)
Sangamo Therapeutics Analyst Ratings
H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $5
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
HC Wainwright & Co. : The Sangamo Therapeutics (SGMO.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $5.00.
Sangamo Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Analyst Ratings
RBC Capital Reiterates Sector Perform on Sangamo Therapeutics, Maintains $2 Price Target
Sangamo Therapeutics Analyst Ratings